Uncategorized

The CMS innovation center will coordinate insurance coverage across states to help patients access new treatments with multi-million-dollar price tags.

Companies grappling with liquidity concerns are looking to trim costs and streamline operations, according to a new survey.

CVRx, Inc . (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the appointment of Kevin Hykes as the Company’s new President and Chief Executive Officer, effective February 12. Hykes will continue to serve on the Company’s Board.

Daré Bioscience, Inc. today announced the successful completion of an end-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA), supporting advancement of Sildenafil Cream, 3.6% (Sildenafil Cream) for the treatment of female sexual arousal disorder.

The Centers for Medicare and Medicaid Services will enter talks with manufacturers to come up with a pricing and rebate scheme that will tie the gene therapies’ cost with their effectiveness.

The new FDA-approved manufacturing process for Kite’s CAR-T cell therapy Yescarta will allow a 14-day turnaround compared to 16 days, the company announced on Tuesday.

ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes.

The agency is seeking answers on how digital health technologies could be used in the detection of prediabetes and Type 2 diabetes.

Experts said M&A, orthopedic procedure backlogs and emerging cardiac markets were among the top trends to watch in the medical device industry this year.

With the deal, Cigna is exiting a sector that’s been a huge source of growth for insurers but has seen its earnings potential shrink.